Alpha Cognition

The revenue base is nascent and payer‑gated. While sequential growth is evident, future quarters depend on plan implementation, prescriber density in LTC, and outcomes from real‑world studies.

Although ZUNVEYL is symptomatic therapy and not subject to the binary risks of disease‑modifying antibodies, demand visibility remains modest until broader formulary integration occurs and repeat utilization sustains at scale. Geographic diversification via CMS in Asia could help, but the timing of approvals and launches is uncertain.